Experimental and Investigational Targeted Therapies for the Management of Fibrosis in NASH: An Update

References

• Younossi Z, Tacke F, Arrese M, et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2019;69(6):2672–2682. doi:10.1002/hep.30251
   PubMed Web of Science ®Google Scholar
• Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol. 2008;214(2):199–210. doi:10.1002/path.2277
   PubMed Web of Science ®Google Scholar
• Roehlen N, Crouchet E, Baumert TF. Liver fibrosis: mechanistic concepts and therapeutic perspectives. Cells. 2020;9(4):875. doi:10.3390/cells9040875
   PubMed Web of Science ®Google Scholar
• Tsuchida T, Friedman SL. Mechanisms of hepatic stellate cell activation. Nat Rev Gastroenterol Hepatol. 2017;14(7):397–411. doi:10.1038/nrgastro.2017.38
   PubMed Web of Science ®Google Scholar
• Kisseleva T, Brenner D. Molecular and cellular mechanisms of liver fibrosis and its regression. Nat Rev Gastroenterol Hepatol. 2020.
   PubMed Web of Science ®Google Scholar
• Lemoinne S, Friedman SL. New and emerging anti-fibrotic therapeutics entering or already in clinical trials in chronic liver diseases. Curr Opin Pharmacol. 2019;49:60–70. doi:10.1016/j.coph.2019.09.006
   PubMed Web of Science ®Google Scholar
• Mohagheghi S, Geramizadeh B, Nikeghbalian S, et al. Intricate role of yes-associated protein1 in human liver cirrhosis: TGF-beta1 still is a giant player. IUBMB Life. 2019;71(10):1453–1464. doi:10.1002/iub.2052
   PubMed Web of Science ®Google Scholar
• Dewidar B, Meyer C, Dooley S, Meindl-Beinker AN. TGF-beta in hepatic stellate cell activation and liver fibrogenesis-updated 2019. Cells. 2019;8(11):1419. doi:10.3390/cells8111419
   PubMed Web of Science ®Google Scholar
• Hellerbrand C, Stefanovic B, Giordano F, Burchardt ER, Brenner DA. The role of TGFbeta1 in initiating hepatic stellate cell activation in vivo. J Hepatol. 1999;30(1):77–87. doi:10.1016/S0168-8278(99)80010-5
   PubMed Web of Science ®Google Scholar
• Arthur MJ, Fibrogenesis II. Metalloproteinases and their inhibitors in liver fibrosis. Am J Physiol Gastrointest Liver Physiol. 2000;279(2):G245–249. doi:10.1152/ajpgi.2000.279.2.G245
   PubMed Web of Science ®Google Scholar
• Campbell JS, Hughes SD, Gilbertson DG, et al. Platelet-derived growth factor C induces liver fibrosis, steatosis, and hepatocellular carcinoma. Proc Natl Acad Sci U S A. 2005;102(9):3389–3394. doi:10.1073/pnas.0409722102
   PubMed Web of Science ®Google Scholar
• Yang L, Kwon J, Popov Y, et al. Vascular endothelial growth factor promotes fibrosis resolution and repair in mice. Gastroenterology. 2014;146(5):1339–1350e1331. doi:10.1053/j.gastro.2014.01.061
   PubMed Web of Science ®Google Scholar
• Noureddin M, Anstee QM, Loomba R. Review article: emerging anti-fibrotic therapies in the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2016;43(11):1109–1123. doi:10.1111/apt.13620
   Web of Science ®Google Scholar
• Duran A, Hernandez ED, Reina-Campos M, et al. p62/SQSTM1 by binding to vitamin d receptor inhibits hepatic stellate cell activity, fibrosis, and liver cancer. Cancer Cell. 2016;30(4):595–609. doi:10.1016/j.ccell.2016.09.004
   PubMed Web of Science ®Google Scholar
• An P, Wei LL, Zhao S, et al. Hepatocyte mitochondria-derived danger signals directly activate hepatic stellate cells and drive progression of liver fibrosis. Nat Commun. 2020;11(1):2362. doi:10.1038/s41467-020-16092-0
   PubMed Web of Science ®Google Scholar
• Ioannou GN. The role of cholesterol in the pathogenesis of NASH. Trends Endocrinol Metab. 2016;27(2):84–95. doi:10.1016/j.tem.2015.11.008
   PubMed Web of Science ®Google Scholar
• Davison BA, Harrison SA, Cotter G, et al. Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials. J Hepatol. 2020.
   Web of Science ®Google Scholar
• Vali Y, Lee J, Boursier J, et al. Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: a systematic review and meta-analysis. J Hepatol. 2020;73(2):252–262. doi:10.1016/j.jhep.2020.03.036
   PubMed Web of Science ®Google Scholar
• Boursier J, Guillaume M, Leroy V, et al. New sequential combinations of noninvasive fibrosis tests provide an accurate diagnosis of advanced fibrosis in NAFLD. J Hepatol. 2019;71(2):389–396. doi:10.1016/j.jhep.2019.04.020
   Web of Science ®Google Scholar
• Sterling RK, Lissen E, Clumeck N. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43(6):1317–1325. doi:10.1002/hep.21178
   PubMed Web of Science ®Google Scholar
• Boursier J, Vergniol J, Guillet A, et al. Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease. J Hepatol. 2016;65(3):570–578. doi:10.1016/j.jhep.2016.04.023
   PubMed Web of Science ®Google Scholar
• de Ledinghen V, Vergniol J. Transient elastography for the diagnosis of liver fibrosis. Expert Rev Med Devices. 2010;7(6):811–823. doi:10.1586/erd.10.46
   PubMed Web of Science ®Google Scholar
• de Ledinghen V, Vergniol J, Foucher J, El-Hajbi F, Merrouche W, Rigalleau V. Feasibility of liver transient elastography with FibroScan using a new probe for obese patients. Liver Int. 2010;30(7):1043–1048. doi:10.1111/j.1478-3231.2010.02258.x
   Web of Science ®Google Scholar
• Lee SJ, Kim SU. Noninvasive monitoring of hepatic steatosis: controlled attenuation parameter and magnetic resonance imaging-proton density fat fraction in patients with nonalcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol. 2019;13(6):523–530. doi:10.1080/17474124.2019.1608820
   PubMed Web of Science ®Google Scholar
• Smith AD, Porter KK, Elkassem AA, Sanyal R, Lockhart ME. Current imaging techniques for noninvasive staging of hepatic fibrosis. AJR Am J Roentgenol. 2019;1–13.
   Web of Science ®Google Scholar
• Jayakumar S, Middleton MS, Lawitz EJ, et al. Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: analysis of data from a Phase II trial of selonsertib. J Hepatol. 2019;70(1):133–141. doi:10.1016/j.jhep.2018.09.024
   PubMed Web of Science ®Google Scholar
• Han MAT, Altayar O, Hamdeh S, et al. Rates of and factors associated with placebo response in trials of pharmacotherapies for nonalcoholic steatohepatitis: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2019;17(4):616–629e626. doi:10.1016/j.cgh.2018.06.011
   Web of Science ®Google Scholar
• Lin SC, Heba E, Bettencourt R, et al. Assessment of treatment response in non-alcoholic steatohepatitis using advanced magnetic resonance imaging. Aliment Pharmacol Ther. 2017;45(6):844–854. doi:10.1111/apt.13951
   Web of Science ®Google Scholar
• Roeb E. Matrix metalloproteinases and liver fibrosis (translational aspects). Matrix Biol. 2018;68–69:463–473. doi:10.1016/j.matbio.2017.12.012
   PubMed Web of Science ®Google Scholar
• Roeb E, Geier A. Nonalcoholic steatohepatitis (NASH) – current treatment recommendations and future developments. Z Gastroenterol. 2019;57(4):508–517. doi:10.1055/a-0784-8827
   Web of Science ®Google Scholar
• Rizzo G, Renga B, Mencarelli A, Pellicciari R, Fiorucci S. Role of FXR in regulating bile acid homeostasis and relevance for human diseases. Curr Drug Targets Immune Endocr Metabol Disord. 2005;5(3):289–303. doi:10.2174/1568008054863781
   PubMedGoogle Scholar
• Venetsanaki V, Karabouta Z, Polyzos SA. Farnesoid X nuclear receptor agonists for the treatment of nonalcoholic steatohepatitis. Eur J Pharmacol. 2019;863:172661. doi:10.1016/j.ejphar.2019.172661
   PubMed Web of Science ®Google Scholar
• Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2015;385(9972):956–965. doi:10.1016/S0140-6736(14)61933-4
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Ratziu V, Loomba R, et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2019;394(10215):2184–2196. doi:10.1016/S0140-6736(19)33041-7
   PubMed Web of Science ®Google Scholar
• Eaton JE, Gores GJ. Long-term outcomes with obeticholic acid in primary biliary cholangitis: reassuring, but still an itch we need to scratch. Lancet Gastroenterol Hepatol. 2019;4(6):417–418. doi:10.1016/S2468-1253(19)30084-6
   Web of Science ®Google Scholar
• Pedrosa M, Seyedkazemi S, Francque S, et al. A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: study design of the TANDEM trial. Contemp Clin Trials. 2020;88:105889. doi:10.1016/j.cct.2019.105889
   PubMed Web of Science ®Google Scholar
• Loomba R, Noureddin M, Kowdley KV, et al. Combination therapies including cilofexor and firsocostat for bridging fibrosis and cirrhosis due to NASH. Hepatology. 2020;73:S116–S117. doi:10.1016/S0168-8278(20)30753-4
   Web of Science ®Google Scholar
• Polyzos SA, Kang ES, Boutari C, Rhee EJ, Mantzoros CS. Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis. Metabolism. 2020;111S:154203. doi:10.1016/j.metabol.2020.154203
   PubMed Web of Science ®Google Scholar
• Harrison SA, Bashir MR, Guy CD, et al. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2019;394(10213):2012–2024. doi:10.1016/S0140-6736(19)32517-6
   PubMed Web of Science ®Google Scholar
• Zhou J, Waskowicz LR, Lim A, et al. A liver-specific thyromimetic, VK2809, decreases hepatosteatosis in glycogen storage disease type Ia. Thyroid. 2019;29(8):1158–1167. doi:10.1089/thy.2019.0007
   PubMed Web of Science ®Google Scholar
• Mondal S, Mugesh G. Novel thyroid hormone analogues, enzyme inhibitors and mimetics, and their action. Mol Cell Endocrinol. 2017;458:91–104. doi:10.1016/j.mce.2017.04.006
   PubMed Web of Science ®Google Scholar
• Yilmaz Y, Eren F, Yonal O, et al. Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease. Eur J Clin Invest. 2010;40(10):887–892. doi:10.1111/j.1365-2362.2010.02338.x
   PubMed Web of Science ®Google Scholar
• Gong Q, Hu Z, Zhang F, et al. Fibroblast growth factor 21 improves hepatic insulin sensitivity by inhibiting mammalian target of rapamycin complex 1 in mice. Hepatology. 2016;64(2):425–438. doi:10.1002/hep.28523
   Web of Science ®Google Scholar
• Degirolamo C, Sabba C, Moschetta A. Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23. Nat Rev Drug Discov. 2016;15(1):51–69.
   PubMed Web of Science ®Google Scholar
• Sanyal A, Charles ED, Neuschwander-Tetri BA, et al. Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial. Lancet. 2019;392(10165):2705–2717. doi:10.1016/S0140-6736(18)31785-9
   PubMed Web of Science ®Google Scholar
• Harrison SA, Neff G, Guy CD, et al. Efficacy and safety of aldafermin, an engineered FGF19 analog, in a randomized, double-blind, placebo-controlled trial of patients with nonalcoholic steatohepatitis. Gastroenterology. 2020.
   Google Scholar
• Baruch A, Wong C, Chinn LW, et al. Antibody-mediated activation of the FGFR1/Klothobeta complex corrects metabolic dysfunction and alters food preference in obese humans. Proc Natl Acad Sci U S A. 2020;117(46):28992–29000. doi:10.1073/pnas.2012073117
   Web of Science ®Google Scholar
• Zarei M, Aguilar-Recarte D, Palomer X, Vazquez-Carrera M. Revealing the role of peroxisome proliferator-activated receptor beta/delta in nonalcoholic fatty liver disease. Metabolism. 2021;114:154342. doi:10.1016/j.metabol.2020.154342
   Web of Science ®Google Scholar
• Fougerat A, Montagner A, Loiseau N, Guillou H, Wahli W. Peroxisome proliferator-activated receptors and their novel ligands as candidates for the treatment of non-alcoholic fatty liver disease. Cells. 2020;9(7):1638. doi:10.3390/cells9071638
   Web of Science ®Google Scholar
• Choudhary NS, Kumar N, Duseja A. Peroxisome proliferator-activated receptors and their agonists in nonalcoholic fatty liver disease. J Clin Exp Hepatol. 2019;9(6):731–739. doi:10.1016/j.jceh.2019.06.004
   Web of Science ®Google Scholar
• Kumar DP, Caffrey R, Marioneaux J, et al. The PPAR alpha/gamma agonist saroglitazar improves insulin resistance and steatohepatitis in a diet induced animal model of nonalcoholic fatty liver disease. Sci Rep. 2020;10(1):9330. doi:10.1038/s41598-020-66458-z
   PubMed Web of Science ®Google Scholar
• Boeckmans J, Natale A, Rombaut M, et al. Anti-NASH drug development hitches a lift on PPAR agonism. Cells. 2019;9(1):37. doi:10.3390/cells9010037
   PubMed Web of Science ®Google Scholar
• Jones D, Boudes PF, Swain MG, et al. Seladelpar (MBX-8025), a selective PPAR-delta agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study. Lancet Gastroenterol Hepatol. 2017;2(10):716–726. doi:10.1016/S2468-1253(17)30246-7
   PubMed Web of Science ®Google Scholar
• Haczeyni F, Wang H, Barn V, et al. The selective peroxisome proliferator-activated receptor-delta agonist seladelpar reverses nonalcoholic steatohepatitis pathology by abrogating lipotoxicity in diabetic obese mice. Hepatol Commun. 2017;1(7):663–674. doi:10.1002/hep4.1072
   PubMed Web of Science ®Google Scholar
• Ratziu V, Harrison SA, Francque S, et al. Elafibranor, an agonist of the peroxisome proliferator-activated receptor-alpha and -delta, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. Gastroenterology. 2016;150(5):1147–1159e1145. doi:10.1053/j.gastro.2016.01.038
   PubMed Web of Science ®Google Scholar
• Newsome PN, Buchholtz K, Cusi K, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2020. doi:10.1056/NEJMoa2028395
   PubMed Web of Science ®Google Scholar
• Liang Z, Li T, Jiang S, et al. AMPK: a novel target for treating hepatic fibrosis. Oncotarget. 2017;8(37):62780–62792. doi:10.18632/oncotarget.19376
   Google Scholar
• Colca JR, McDonald WG, McCommis KS, Finck BN. Treating fatty liver disease by modulating mitochondrial pyruvate metabolism. Hepatol Commun. 2017;1(3):193–197. doi:10.1002/hep4.1036
   Web of Science ®Google Scholar
• van den Hoek AM, Pieterman EJ, van der Hoorn JW, et al. Icosabutate exerts beneficial effects upon insulin sensitivity, hepatic inflammation, lipotoxicity, and fibrosis in mice. Hepatol Commun. 2020;4(2):193–207. doi:10.1002/hep4.1453
   PubMed Web of Science ®Google Scholar
• Stokman G, van den Hoek AM, Denker Thorbekk D, et al. Dual targeting of hepatic fibrosis and atherogenesis by icosabutate, an engineered eicosapentaenoic acid derivative. Liver Int. 2020;40(11):2860–2876. doi:10.1111/liv.14643
   PubMed Web of Science ®Google Scholar
• Iruarrizaga-Lejarreta M, Varela-Rey M, Fernandez-Ramos D, et al. Role of aramchol in steatohepatitis and fibrosis in mice. Hepatol Commun. 2017;1(9):911–927. doi:10.1002/hep4.1107
   PubMed Web of Science ®Google Scholar
• Ratziu V, de Guevara L, Safadi R, et al. One-year results of the global phase 2b randomized placebo controlled ARREST trial of aramchol, a stearoyl CoA desaturase modulator in NASH patients. Hepatology. 2018;68:LB–5.
   Google Scholar
• Safadi R, Konikoff FM, Mahamid M, et al. The fatty acid-bile acid conjugate aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2014;12(12):2085–2091e2081. doi:10.1016/j.cgh.2014.04.038
   PubMed Web of Science ®Google Scholar
• Weston CJ, Shepherd EL, Claridge LC, et al. Vascular adhesion protein-1 promotes liver inflammation and drives hepatic fibrosis. J Clin Invest. 2015;125(2):501–520. doi:10.1172/JCI73722
   PubMed Web of Science ®Google Scholar
• Tricot T, De Boeck J, Verfaillie C. Alternative cell sources for liver parenchyma repopulation: where do we stand? Cells. 2020;9(3):566. doi:10.3390/cells9030566
   Web of Science ®Google Scholar
• Lefere S, Devisscher L, Tacke F. Targeting CCR2/5 in the treatment of nonalcoholic steatohepatitis (NASH) and fibrosis: opportunities and challenges. Expert Opin Investig Drugs. 2020;29(2):89–92. doi:10.1080/13543784.2020.1718106
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Stepanova M, Lawitz E, et al. Improvement of hepatic fibrosis and patient-reported outcomes in non-alcoholic steatohepatitis treated with selonsertib. Liver Int. 2018;38(10):1849–1859. doi:10.1111/liv.13706
   PubMed Web of Science ®Google Scholar